Eli Lilly: to present study data
(CercleFinance.com) - Eli Lilly today announced that data from the Verzenio (abemaciclib) and Retevmo (selpercatinib) studies will be presented at the European Society for Medical Oncology (ESMO) 2022 Congress, to be held from tomorrow, 9 to 13 September 2022.
Lilly will present interim overall survival results from the double-blind, randomised MONARCH 3 study of Verzenio, as well as final overall survival results from the phase 2 monarcHER study in advanced breast cancer.
Longer-term follow-up data for patients with medullary thyroid cancer and data on continued treatment with Retevmo will also be presented.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Lilly will present interim overall survival results from the double-blind, randomised MONARCH 3 study of Verzenio, as well as final overall survival results from the phase 2 monarcHER study in advanced breast cancer.
Longer-term follow-up data for patients with medullary thyroid cancer and data on continued treatment with Retevmo will also be presented.
Copyright (c) 2022 CercleFinance.com. All rights reserved.